Summary
Acetylsalicylic acid (ASA) is a strong, irreversible inhibitor of platelet aggregation, but loses this activity following first-pass deacetylation to salicylic acid (SA). In order to compare the bioavailability of unchanged ASA from rapid- and slow-release formulations, the single-dose concentration profiles of ASA and SA were studied in healthy volunteers following intake of two different rapid-release (conventional and effervescent tablets) and three different slow-release (microencapsulated ASA in tablets and in capsules, and enteric-coated tablets) formulations of ASA, and of one slow-release formulation of sodium salicylate. Since anti-platelet therapy with ASA is often combined with dipyridamol, the influence of this drug was also examined. The concentrations of ASA and SA were measured by high-pressure liquid chromatography. While the bioavailability of SA from the 5 ASA formulations was essentially equal and similar to that of the salicylate formulation, the bioavailability and peak concentrations of ASA appeared to be the much greater after rapid-release than after slow-release formulations. Indeed, ASA was only rarely detected in systemic blood following intake of slow-release ASA. Co-administered dipyridamol did not significantly influence the kinetics of ASA or SA. It appears that rapid-release formulations of ASA should be prefered in anti-platelet therapy, either alone or in combination with dipyridamol.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Fields WS, Lemak NA, Frankowski RF, Hardy RJ (1977) Controlled trial of aspirin in cerebral ischemia. Stroke 8: 301–314
Barnett HJM et al. (Candadian Cooperative Study Group) (1978) A Randomized trial of aspirin and sulfonpyrazone in threatened stroke. N Engl J Med 299: 53–59
Harter HR, Burch JW, Majerus PW, Stanford N, Delmez JA, Anderson CB, Weerts CA (1979) Prevention of thrombosis in patients on hemodialysis by low-dose aspirin. N Engl J Med 301: 577–579
Olsson JE, Brechter C, Bäcklund H, Krook H, Müller R, Nitelius E, Olsson O, Tornberg A (1980) Anticoagulant vs antiplatelet therapy as prophylactic againts cerebral infarction in transient ischemic attacks. Stroke 11: 1–9
Breddin K, Loew D, Lechner K, Überla K, Walter (1980) Secondary prevention of myocardial infarction: a comparison of acetylsalicylic acid, placebo and phenprocoumon. Haemostasis 9: 325–344
Mustard JF, Kinlough-Rathbone RL, Packham MA (1980) Prostaglandins and platelets. Annu Rev Med 31: 89–96
Vane JR (1971) Inhibition of prostaglandin synthesis as a mechanism of action of aspirin-like drugs. Nature, New Biol 231: 232–240
Vargaftig BB (1978) Salicylic acid fails to inhibit generation of thromboxane A2 activity in platelets after in vivo administration to the rat. J Pharm Pharmacol 30: 101–106
Brantmark B, Hedner U, Melander A, Wåhlin-Boll E (1981) Salicylate inhibition of antiplatelet effect of aspirin. Lancet II: 1349
Vargaftig BB (1978) The inhibition of cyclo-oxygenase of rabbit platelets by aspirin is prevented by salicylic acid and by phenanthrolines. Eur J Pharmacol 50: 231–241
Levy G (1979) Pharmacokinetics of salicylate in man. Drug Metab Rev 9: 3–19
The Persantine-Aspirin Reinfarction Study Research Group (1980) Persantine and aspirin in coronary heart disease. Circulation 62: 449–461
Wåhlin-Boll E, Brantmark B, Hanson A, Melander A, Nilsson C (1981) High-pressure liquid chromatographic determination of acetylsalicylic acid, salicylic acid, diflunisal, indomethacin, indoprofen and indobufen. Eur J Clin Pharmacol 20: 375–378
Bogentoft C, Carlsson I, Ekenved G, Magnusson A (1978) Influence of food on the absorption of acetylsalicylic acid from enteric coated-dosage forms. Eur J Clin Pharmacol 14: 351–355
Ali M, McDonald JWD, Thiessen JJ, Coates PE (1980) Plasma acetylsalicylate and salicylate and platelet cyclooxygenase activity following plain and enteric-coated aspirin. Stroke 11: 9–13
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Brantmark, B., Wåhlin-Boll, E. & Melander, A. Bioavailability of acetylsalicylic acid and salicylic acid from rapid-and slow-release formulations, and in combination with dipyridamol. Eur J Clin Pharmacol 22, 309–314 (1982). https://doi.org/10.1007/BF00548398
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00548398